Dosing & Uses
Dosage Forms & Strengths
tablets
- 100 mg
Overactive Bladder
Indicated for dysuria, increased urinary frequency/incontinence, nocturia, suprapubic pain, urinary incontinence, urinary tract irritation, urinary urgency
100-200 mg PO q6-8hr
Dosage Forms & Strengths
tablets
- 100 mg
Dysuria, Urinary Frequency
Indicated for dysuria, increased urinary frequency, nocturia, suprapubic pain, urinary incontinence, urinary tract irritation, urinary urgency
<12 years: Not recommended; safety and efficacy not established
≥12 years: 100-200 mg PO q6-8hr
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (2)
- pramlintide
pramlintide, flavoxate. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.
- secretin
flavoxate decreases effects of secretin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Concomitant use of anticholinergic drugs may cause a hyporesponse to stimulation testing with secretin. Discontinue anticholinergic drugs at least 5 half-lives before administering secretin.
Monitor Closely (89)
- aclidinium
flavoxate and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- amantadine
flavoxate, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.
- amitriptyline
flavoxate and amitriptyline both decrease cholinergic effects/transmission. Modify Therapy/Monitor Closely.
- amoxapine
flavoxate and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- anticholinergic/sedative combos
anticholinergic/sedative combos and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- aripiprazole
flavoxate decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.
aripiprazole increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - atracurium
atracurium and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- atropine
atropine and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- atropine IV/IM
atropine IV/IM and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- belladonna alkaloids
belladonna alkaloids and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- belladonna and opium
flavoxate and belladonna and opium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- benperidol
flavoxate decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor.
benperidol increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - benztropine
benztropine and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use.
- bethanechol
bethanechol increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- carbachol
carbachol increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- cevimeline
cevimeline increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- chlorpromazine
flavoxate decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.
chlorpromazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - cisatracurium
cisatracurium and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- clomipramine
flavoxate and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- clozapine
flavoxate decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor.
clozapine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - cyclizine
cyclizine and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- cyclobenzaprine
cyclobenzaprine and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- darifenacin
darifenacin and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- dicyclomine
dicyclomine and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- diphenhydramine
diphenhydramine and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- donepezil
donepezil increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- donepezil transdermal
donepezil transdermal, flavoxate. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.
- dosulepin
flavoxate and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- doxepin
flavoxate and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- droperidol
flavoxate decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - echothiophate iodide
echothiophate iodide increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- fesoterodine
fesoterodine and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- fluphenazine
flavoxate decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor.
fluphenazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - galantamine
galantamine increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- glycopyrrolate
flavoxate and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- glycopyrrolate inhaled
flavoxate and glycopyrrolate inhaled both decrease cholinergic effects/transmission. Use Caution/Monitor.
- haloperidol
flavoxate decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor.
haloperidol increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - henbane
flavoxate and henbane both decrease cholinergic effects/transmission. Use Caution/Monitor.
- homatropine
flavoxate and homatropine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- huperzine A
huperzine A increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- hyoscyamine
flavoxate and hyoscyamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- hyoscyamine spray
flavoxate and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- iloperidone
flavoxate decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor.
iloperidone increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - imipramine
flavoxate and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- ipratropium
flavoxate and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- lofepramine
flavoxate and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- loxapine
flavoxate decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.
loxapine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - loxapine inhaled
loxapine inhaled increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
flavoxate decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor. - maprotiline
flavoxate and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- meclizine
flavoxate and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- methscopolamine
flavoxate and methscopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- neostigmine
neostigmine increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nortriptyline
flavoxate and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- olanzapine
flavoxate decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.
olanzapine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - onabotulinumtoxinA
onabotulinumtoxinA and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- orphenadrine
flavoxate and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin
flavoxate and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin topical
flavoxate and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin transdermal
flavoxate and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.
- paliperidone
flavoxate decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor.
paliperidone increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - pancuronium
flavoxate and pancuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- perphenazine
flavoxate decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of perphenazine by pharmacodynamic antagonism. Use Caution/Monitor.
perphenazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - physostigmine
physostigmine increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pilocarpine
pilocarpine increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pimozide
flavoxate decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor.
pimozide increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - pralidoxime
flavoxate and pralidoxime both decrease cholinergic effects/transmission. Use Caution/Monitor.
- prochlorperazine
flavoxate decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - promethazine
flavoxate decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.
promethazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - propantheline
flavoxate and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- protriptyline
flavoxate and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- pyridostigmine
pyridostigmine increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- quetiapine
flavoxate decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of quetiapine by pharmacodynamic antagonism. Use Caution/Monitor.
quetiapine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - rapacuronium
flavoxate and rapacuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- risperidone
flavoxate decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.
risperidone increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - rocuronium
flavoxate and rocuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- scopolamine
flavoxate and scopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- solifenacin
flavoxate and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- succinylcholine
succinylcholine increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- thioridazine
flavoxate decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor.
thioridazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - thiothixene
flavoxate decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.
thiothixene increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - tiotropium
flavoxate and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- tolterodine
flavoxate and tolterodine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- trifluoperazine
flavoxate decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.
trifluoperazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - trihexyphenidyl
flavoxate and trihexyphenidyl both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.
- trimipramine
flavoxate and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- trospium chloride
flavoxate and trospium chloride both decrease cholinergic effects/transmission. Use Caution/Monitor.
- vecuronium
flavoxate and vecuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- ziprasidone
flavoxate decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.
ziprasidone increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - zotepine
flavoxate decreases levels of zotepine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
flavoxate decreases levels of zotepine by pharmacodynamic antagonism. Use Caution/Monitor.
Minor (8)
- atenolol
flavoxate increases effects of atenolol by unspecified interaction mechanism. Minor/Significance Unknown.
- desipramine
flavoxate and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- digoxin
flavoxate increases effects of digoxin by unspecified interaction mechanism. Minor/Significance Unknown.
- dimenhydrinate
dimenhydrinate increases toxicity of flavoxate by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- donepezil
donepezil decreases effects of flavoxate by pharmacodynamic antagonism. Minor/Significance Unknown.
- galantamine
galantamine decreases effects of flavoxate by pharmacodynamic antagonism. Minor/Significance Unknown.
- levodopa
flavoxate, levodopa. Other (see comment). Minor/Significance Unknown. Comment: Anticholinergic agents may enhance the therapeutic effects of levodopa; however, anticholinergic agents can exacerbate tardive dyskinesia. In high dosage, anticholinergics may decrease the effects of levodopa by delaying its GI absorption. .
- trazodone
flavoxate and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
Adverse Effects
Frequency Not Defined
Abdominal pain
Blurred vision
Confusion
Constipation
Disturbance in ocular accommodation
Drowsiness
Dry mouth/throat
Dysuria
Eosinophilia
Headache
Hyperpyrexia
Increased ocular tension
Nausea
Nervousness
Palpitation
Tachycardia
Urticaria
Vertigo
Vomiting
Warnings
Contraindications
Obstructive uropathy, pyloric/duodenal obstruction, ileus, GI bleeding, achalasia
Cautions
Use with caution in patients with glaucoma
May impair ability to perform hazardous tasks
May cause ocular disturbances; advice patients of potential effects
Vertigo may occur
Pregnancy & Lactation
Pregnancy Category: B
Lactation: not known if excreted in breast milk, use caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Anticholinergic smooth muscle relaxant that inhibits phosphodiesterase and counteracts muscle spasm in urinary tract; also relaxes detrusor muscle
Pharmacokinetics
Onset: 55 min
Peak Effect: 112 min
Excretion: Urine (10-30%)
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
flavoxate oral - | 100 mg tablet | ![]() | |
flavoxate oral - | 100 mg tablet | ![]() |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.